A STUDY TO ASSESS TWO DIFFERENT TECHNOLOGIES OF THERAPEUTIC PLASMA EXCHANGE MODALITY IN KIDNEY DISEASES
Not Applicable
- Conditions
- Health Condition 1: N29- Other disorders of kidney and ureter in diseases classified elsewhere
- Registration Number
- CTRI/2022/07/043871
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.No evidence of active infection
2.Willing to give informed consent for the procedure (In patients who are incompetent to consent, consent shall be taken from the surrogate)
3.Those who not enrolled in any other study
Exclusion Criteria
1.Pregnancy
2.Microbiological or radiological evidence of active infection
3.Known allergy to Plasma, Protamine or Heparin.
4.Severe systemic illness like HIV
5.Patients with vasculitis due to secondary causes (diagnosis of a different rheumatic disease, Hepatitis B, Hepatitis C, HIV infection)
6.Mechanically ventilated patients
7.Renal or any other transplant recepients would be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a.Compare the centrifugal and membrane filtration technologies for TPE in renal disease patients in terms of their efficacy in plasma removal. <br/ ><br>b.Compare the Post exchange clinical, biochemical, and hematological profile in the two groups <br/ ><br>c.Calculation of the TPE procedure costs in the two modalities <br/ ><br>Timepoint: recruitment 12 months <br/ ><br>results and analysis 2months
- Secondary Outcome Measures
Name Time Method Patient Outcome- Adverse events and Morbidity and mortality at 30 days and 90 days TPE cycle completionTimepoint: at 30 and 90 days post TPE cycle completion